Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Global Opportunity Analysis and Industry Forecast, 2023-2030

Early Toxicity Testing Market

Industry:  Life Sciences & Healthcare | Publish Date: May 2023 | No of Pages:  306 | No. Tables:  235 | No. Figures:  185

Market Definition

The global Early Toxicity Testing (ETT) Market size was valued at USD 8.92 billion in 2022 and is predicted to reach USD 14.39 billion by 2030, registering a CAGR of 5.3% from 2023 to 2030. Early toxicity testing is a process that involves evaluating the potential toxicity or adverse effects of drugs, chemicals, or other substances at an early stage of development, typically in vitro or in animal models, before they are tested in humans. Early toxicity testing aims to identify any potential safety concerns with a substance and determine whether it is safe to proceed with further development and testing.

Early toxicity testing typically involves a range of tests and assays, such as cell viability assays, genotoxicity assays, and pharmacokinetic studies. The industry has emerged as a crucial step in drug development, allowing researchers and pharmaceutical companies to identify the potentially toxic effects of drugs before being tested on humans. By identifying potential toxic effects early on in the drug development process, researchers and pharmaceutical companies can avoid investing significant resources in drugs that are unlikely to be successful, ultimately saving time and money while bringing safe and effective treatments to patients more quickly.

The ETT industry has significant growth prospects, as both developed and developing countries are placing considerable emphasis on R&D activities and allocating a greater portion of their GDP budgets toward developing novel drugs and technologies for treating life-threatening diseases. As per Pharmaprojects, the aggregate count of pipeline preclinical drug development activities surged to 11,351 in 2022, representing an increase from the preceding figure of 10,223 in 2021.

Growth in Pharmaceutical & Biotechnology R&D Activities

The rise in the prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular diseases, has increased the need for new and effective treatments. As a result, pharmaceutical and biotechnology companies are investing heavily in R&D activities to develop new drugs and therapies for these diseases. To ensure the safety of new medicines and treatments, extensive toxicological testing is required to identify any potential safety issues or adverse effects.

Therefore, early toxicity testing ensures that only safe and effective drugs are tested in clinical trials, reducing the risk of harm to trial participants. As a result, the growth in demand for new drugs and therapies combined with the need for extensive toxicological testing to ensure their safety propels the demand for early toxicity testing services.

Rising demand for food processing as well as concerns related to its safety

The rising demand for food processing and concerns related to food safety are major drivers of the growth of the early toxicity testing industry. The global food industry is constantly expanding, and consequently, there is a rise in the need to ensure the safety of food products. Early toxicity testing plays a crucial role in this process by identifying potentially harmful substances in food and ensuring that food products are safe for consumption.

Several factors contribute to concerns related to food safety, such as the use of pesticides, genetically modified organisms (GMOs), and other chemicals in food production. Early toxicity testing allows for assessing the potential toxicity of these substances, ensuring that they are safe for human consumption.

In addition, there is growing consumer awareness and concerns about the safety of food products, which have led to increased regulatory scrutiny and stricter safety standards. Early toxicity testing is essential to compliance with these regulations and standards, as it identifies potential hazards and helps ensure that food products are safe for consumption.

 

Growing Consumer Awareness about Hazardous Cosmetic Products

The increasing awareness among consumers about the potential hazards associated with cosmetic products that may cause adverse reactions on the skin has compelled companies to undertake early toxicity testing. Early toxicity testing helps assess the potential effects of cosmetic ingredients on living organisms, including skin irritation, sensitization, and phototoxicity. This testing can be performed on various organisms, including human cells, tissues, and volunteers. It can identify the potential toxicity of cosmetic ingredients in the early stages of development.

Moreover, regulatory bodies such as the Food and Drug Administration (FDA) and the European Commission require companies to conduct toxicity testing on cosmetic ingredients to evaluate their potential impact on human health. This testing is critical for obtaining regulatory approval for the use and distribution of cosmetic products. Thus, propelling the growth of the early toxicity testing industry.

Stringent regulations and high costs associated with the testing process

Early toxicity testing can be expensive, particularly for large-scale studies involving a variety of organisms and multiple endpoints. The high cost of toxicity testing can be a significant deterrent for small and medium-sized companies that may need more financial resources to conduct extensive testing.

Moreover, the growth of the early toxicity testing market is restrained due to the rigorous and extensive testing required for drug development and safety, as set forth by regulatory bodies such as the U.S. FDA and the European Medicines Agency. These stringent regulations can prolong the approval process for new drugs, further delaying their arrival in the market. It is expected that this delay will impede the growth of the market.

 

The introduction of 3D cell culture and bioinformatics

3D cell culture enables the development of more physiologically relevant in vitro models, which mimic living tissues' complex interactions and architecture in a better manner. This allows for more accurate and reliable toxicity testing than traditional 2D cell culture models. Additionally, 3D cell culture can reduce the need for animal testing, which is more ethical and cost-effective in the long run.

Moreover, bioinformatics provides a powerful tool for analyzing large data sets generated by high-throughput screening methods. Integrating bioinformatics with 3D cell culture enables the identification of biomarkers that can be used to predict drug toxicity and efficacy more accurately than before. This approach can streamline drug development by reducing the number of compounds that require extensive in vivo testing.

Furthermore, combining 3D cell culture and bioinformatics creates opportunities for personalized medicine. Patient-specific cells can be cultured in a 3D environment and subjected to high-throughput screening using bioinformatics, leading to the identification of optimal drug treatments for individual patients. This approach could revolutionize the drug development process and improve patient outcomes.

Asia-Pacific is Dominating in Terms of the Higher Number of Early Toxicity Tests

The Asia-Pacific region is expected to dominate the early toxicity testing industry, primarily due to its emphasis on R&D activities and the expansion of this sector in countries such as Japan, South Korea, and Australia. As of March 2021, the National Center for Biotechnology Information reports that the pharmaceutical industry in this region has been growing at an annual rate of 5.8% since 2017.

Moreover, the incidence of strokes is increasing in certain countries of the Asia-Pacific region, including China, India, Japan, and South Korea. This, in turn, is driving growth in the ETT industry. Stroke is a critical area of concern for early toxicity testing, as it plays a vital role in developing new drugs and therapies for stroke patients. According to the National Center for Biotechnology Information, as of March 2022, it was stated that there were 3.4 million incident cases of stroke, 17.8 million prevalent cases of stroke, and 2.3 million deaths from stroke among the Chinese population aged 40 years and older.

Furthermore, the rapidly growing drug development by pharmaceutical and biotech companies across the region fosters the growth of the early toxicity testing market. According to the Korea Drug Development Fund (KDDF), a total of 559 new pipelines were being developed by domestic companies as of 2021. This includes channels for various therapeutic areas, such as oncology, rare diseases, and infectious diseases.

North America Witnessed Substantial Growth

The presence of prominent companies, including Danaher Corporation, Charles River Laboratories, and Thermo Fisher Scientific Inc. in the region, that are engaged in early toxicity testing of various drug discoveries drives the market growth. Moreover, the region has a huge number of Contract Research Organizations (CROs), mostly in the U.S., as CROs play an important role in the growth of this industry by providing outsourced research services to pharmaceutical and biotechnology companies that need to conduct toxicity testing as part of their drug development programs.

Moreover, the growth of the biotechnology and pharmaceutical sectors in this region has resulted in a surge in drug research and development endeavors, leading to a greater need for early toxicity testing services that can facilitate the development of novel vaccines and medications. According to a report published by the Government of Canada, Canada is the 9th largest pharmaceutical market in the world, with over 1,100 small and medium-sized enterprises and USD 1.2 billion invested in R&D activities in 2019.

Furthermore, the region is excelling in terms of the early toxicity testing market, owing to the presence of developed economies that are dedicatedly involved in the high number of drugs under R&D. According to the Pharmaprojects, the U.S. had a total number of 10,736 drugs under R&D, followed by Canada with 2,182 drugs under R&D in 2022.

 

Competitive Landscape

Various market players that operate in the early toxicity testing industry include Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG. These market players are adopting strategies such as business expansion and acquisition across various regions to maintain their dominance in the early toxicity testing market.

For instance, in April 2023, Agilent Technologies Inc. acquired Avida Biomed, a contract research organization specializing in vitro and in vivo toxicity testing, including ADME/DMPK studies. This acquisition will expand Agilent's capability in preclinical drug development, including early toxicity testing, and complement its existing portfolio of pharmaceutical research and development solutions.

Moreover, in July 2022, Inotiv, Inc. announced the expansion of its genetic toxicology offerings at its Rockville, Maryland facility by adding Good Laboratory Practice (GLP) assays to its portfolio, enabling it to conduct more comprehensive early toxicity testing. With this expansion, Inotiv can offer clients a broader range of genetic toxicology services, including Ames testing, in vitro micronucleus testing, and in vitro chromosomal aberration testing.

In addition, in November 2021, WuXi Apptec opened a new facility in Philadelphia to expand its testing capabilities to support global customers with gene and cell therapy development and manufacturing services. The new facility offers cGMP-compliant testing services, including lot release, stability testing, and analytical method development and validation.

EARLY TOXICITY TESTING MARKET KEY SEGMENTS

By Technique

  • In Vivo

  • In Vitro

    • Cell Culture    

    • PCR    

    • ELISA    

    • Western Blotting    

    • Protein Binding Assays    

  • In Silico    

By Toxicity Endpoint

  • Genotoxicity    

  • Dermal Toxicity 

  • Skin Toxicity 

  • Ocular Toxicity    

  • Phototoxicity    

  • Others    

By End User

  • Pharmaceutical Industry    

  • Cosmetic Industry    

  • Chemical Industry    

  • Food Industry     

  • Others        

By Geography

  • North America

    • The U.S.

    • Canada

    • Mexico

  • Europe

    • The U.K.    

    • Germany    

    • France    

    • Italy    

    • Spain    

    • Netherlands    

    • Denmark    

    • Finland    

    • Norway    

    • Sweden    

    • Russia     

    • Rest of Europe        

  • Asia-Pacific

    • Australia    

    • China    

    • India    

    • Indonesia    

    • Japan    

    • Singapore    

    • South Korea    

    • Taiwan    

    • Thailand    

    • Rest of Asia Pacific    

  • RoW

    • Latin America    

    • Middle East    

    • Africa

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2022

USD 8.92 Billion

Revenue Forecast in 2030

USD 14.39 Billion

Growth Rate

CAGR of 5.3% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Billion (USD)

Growth Factors

Growth in pharmaceutical & biotechnology R&D activities

Rising demand for food processing as well as concerns related to its safety

Countries Covered

28

Companies Profiled

15

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent to up to 80 analysts’ working hours) after purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

column chart

Test

1. INTRODUCTION

1.1.     REPORT DESCRIPTION

1.2.     WHO SHOULD READ THIS REPORT 

1.3.     KEY MARKET SEGMENTS

1.4.     RESEARCH METHODOLOGY

1.4.1   SECONDARY RESEARCH

1.4.2   DATA ANALYSIS FRAMEWORK

1.4.3   MARKET SIZE ESTIMATION

1.4.4   FORECASTING

1.4.5   PRIMARY RESEARCH AND DATA VALIDATION

2. EARLY TOXICITY TESTING MARKET – EXECUTIVE SUMMARY

2.1.     MARKET SNAPSHOT, 2022 - 2030, MILLION USD

3. MARKET OVERVIEW

3.1.     MARKET DEFINITION AND SCOPE

3.2.     MARKET DYNAMICS

3.2.1   DRIVERS

3.2.1.1.          GROWTH IN RESEARCH AND DEVELOPMENT ACTIVITIES

3.2.1.2.          GROWTH IN PREVALENCE OF CHRONIC DISEASES AND NEED FOR NEW TREATMENTS

3.2.2   RESTRAINTS

3.2.2.1.          STRINGENT REGULATIONS

3.2.3   OPPORTUNITIES

3.2.3.1.          DEVELOPMENT OF NEW TECHNOLOGIES

4. MARKET SHARE ANALYSIS

4.1.     MARKET SHARE ANALYSIS OF TOP EARLY TOXICITY TESTING PROVIDERS, 2022

5. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

5.1.     OVERVIEW

5.2.     IN VIVO

5.2.1   IN VIVO MARKET, BY REGION

5.3.     IN VITRO

5.3.1   GLOBAL IN VITRO MARKET, BY TECHNIQUE

5.3.1.1.          CELL CULTURE MARKET, BY REGION

5.3.1.2.          PCR MARKET, BY REGION

5.3.1.3.          ELISA MARKET, BY REGION

5.3.1.4.          WESTERN BLOTTING MARKET, BY REGION

5.3.1.5.          PROTEIN BINDING ASSAYS MARKET, BY REGION

5.3.2   IN VITRO MARKET, BY REGION

5.4.     IN SILICO

5.4.1   IN SILICO MARKET, BY REGION

6. GLOBAL EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

6.1.     OVERVIEW

6.2.     GENOTOXICITY

6.2.1   GENOTOXICITY MARKET, BY REGION

6.3.     DERMAL TOXICITY

6.3.1   DERMAL TOXICITY MARKET, BY REGION

6.4.     SKIN TOXICITY

6.4.1   SKIN TOXICITY MARKET, BY REGION

6.5.     OCULAR TOXICITY

6.5.1   OCULAR TOXICITY MARKET, BY REGION

6.6.     PHOTOTOXICITY

6.6.1   PHOTOTOXICITY MARKET, BY REGION

6.7.     OTHERS

6.7.1   OTHERS MARKET, BY REGION

7. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USER

7.1.     OVERVIEW

7.2.     PHARMACEUTICAL INDUSTRY

7.2.1   PHARMACEUTICAL INDUSTRY MARKET, BY REGION

7.3.     COSMETIC INDUSTRY

7.3.1   COSMETIC INDUSTRY MARKET, BY REGION

7.4.     CHEMICAL INDUSTRY

7.4.1   CHEMICAL INDUSTRY MARKET, BY REGION

7.5.     FOOD INDUSTRY

7.5.1   FOOD INDUSTRY MARKET, BY REGION

7.6.     OTHERS

7.6.1   OTHERS MARKET, BY REGION

8. GLOBAL EARLY TOXICITY TESTING MARKET, BY REGION

8.1.     OVERVIEW

8.2.     NORTH AMERICA

8.2.1   NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.2.1.1.          NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE

8.2.2   NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.2.3   NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER

8.2.4   NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY

8.2.4.1.          U.S.

8.2.4.1.1.    U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.2.4.1.1.1.   U.S. IN VITRO MARKET, BY TECHNIQUE

8.2.4.1.2.    U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.2.4.1.3.    U.S. EARLY TOXICITY TESTING MARKET, BY END USER

8.2.4.2.          CANADA

8.2.4.2.1.    CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.2.4.2.1.1.   CANADA IN VITRO MARKET, BY TECHNIQUE

8.2.4.2.2.    CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.2.4.2.3.    CANADA EARLY TOXICITY TESTING MARKET, BY END USER

8.2.4.3.          MEXICO

8.2.4.3.1.    MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.2.4.3.1.1.   MEXICO IN VITRO MARKET, BY TECHNIQUE

8.2.4.3.2.    MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.2.4.3.3.    MEXICO EARLY TOXICITY TESTING MARKET, BY END USER

8.3.     EUROPE

8.3.1   EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.1.1.          EUROPE IN VITRO MARKET, BY TECHNIQUE

8.3.2   EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.3   EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4   EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY

8.3.4.1.          UK

8.3.4.1.1.    UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.1.1.1.   UK IN VITRO MARKET, BY TECHNIQUE

8.3.4.1.2.    UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.1.3.    UK EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.2.          GERMANY

8.3.4.2.1.    GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.2.1.1.   GERMANY IN VITRO MARKET, BY TECHNIQUE

8.3.4.2.2.    GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.2.3.    GERMANY EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.3.          FRANCE

8.3.4.3.1.    FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.3.1.1.   FRANCE IN VITRO MARKET, BY TECHNIQUE

8.3.4.3.2.    FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.3.3.    FRANCE EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.4.          ITALY

8.3.4.4.1.    ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.4.1.1.   ITALY IN VITRO MARKET, BY TECHNIQUE

8.3.4.4.2.    ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.4.3.    ITALY EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.5.          SPAIN

8.3.4.5.1.    SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.5.1.1.   SPAIN IN VITRO MARKET, BY TECHNIQUE

8.3.4.5.2.    SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.5.3.    SPAIN EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.6.          NETHERLANDS

8.3.4.6.1.    NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.6.1.1.   NETHERLANDS IN VITRO MARKET, BY TECHNIQUE

8.3.4.6.2.    NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.6.3.    NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.7.          DENMARK

8.3.4.7.1.    DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.7.1.1.   DENMARK IN VITRO MARKET, BY TECHNIQUE

8.3.4.7.2.    DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.7.3.    DENMARK EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.8.          FINLAND

8.3.4.8.1.    FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.8.1.1.   FINLAND IN VITRO MARKET, BY TECHNIQUE

8.3.4.8.2.    FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.8.3.    FINLAND EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.9.          NORWAY

8.3.4.9.1.    NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.9.1.1.   NORWAY IN VITRO MARKET, BY TECHNIQUE

8.3.4.9.2.    NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.9.3.    NORWAY EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.10.        SWEDEN

8.3.4.10.1.  SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.10.1.1. SWEDEN IN VITRO MARKET, BY TECHNIQUE

8.3.4.10.2.  SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.10.3.  SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.11.        RUSSIA

8.3.4.11.1.  RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.11.1.1. RUSSIA IN VITRO MARKET, BY TECHNIQUE

8.3.4.11.2.  RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.11.3.  RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER

8.3.4.12.        REST OF EUROPE

8.3.4.12.1.  REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.3.4.12.1.1. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE

8.3.4.12.2.  REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.3.4.12.3.  REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

8.4.     ASIA-PACIFIC

8.4.1   ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.1.1.          ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE

8.4.2   ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.3   ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4   ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY

8.4.4.1.          AUSTRALIA

8.4.4.1.1.    AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.1.1.1.   AUSTRALIA IN VITRO MARKET, BY TECHNIQUE

8.4.4.1.2.    AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.1.3.    AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.2.          CHINA

8.4.4.2.1.    CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.2.1.1.   CHINA IN VITRO MARKET, BY TECHNIQUE

8.4.4.2.2.    CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.2.3.    CHINA EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.3.          INDIA

8.4.4.3.1.    INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.3.1.1.   INDIA IN VITRO MARKET, BY TECHNIQUE

8.4.4.3.2.    INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.3.3.    INDIA EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.4.          INDONESIA

8.4.4.4.1.    INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.4.1.1.   INDONESIA IN VITRO MARKET, BY TECHNIQUE

8.4.4.4.2.    INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.4.3.    INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.5.          JAPAN

8.4.4.5.1.    JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.5.1.1.   JAPAN IN VITRO MARKET, BY TECHNIQUE

8.4.4.5.2.    JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.5.3.    JAPAN EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.6.          SINGAPORE

8.4.4.6.1.    SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.6.1.1.   SINGAPORE IN VITRO MARKET, BY TECHNIQUE

8.4.4.6.2.    SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.6.3.    SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.7.          SOUTH KOREA

8.4.4.7.1.    SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.7.1.1.   SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE

8.4.4.7.2.    SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.7.3.    SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.8.          TAIWAN

8.4.4.8.1.    TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.8.1.1.   TAIWAN IN VITRO MARKET, BY TECHNIQUE

8.4.4.8.2.    TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.8.3.    TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.9.          THAILAND

8.4.4.9.1.    THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.9.1.1.   THAILAND IN VITRO MARKET, BY TECHNIQUE

8.4.4.9.2.    THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.9.3.    THAILAND EARLY TOXICITY TESTING MARKET, BY END USER

8.4.4.10.        REST OF ASIA-PACIFIC

8.4.4.10.1.  REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.4.4.10.1.1. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE

8.4.4.10.2.  REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.4.4.10.3.  REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER

8.5.     REST OF WORLD

8.5.1   REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.5.1.1.          REST OF WORLD IN VITRO MARKET, BY TECHNIQUE

8.5.2   REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.5.3   REST OF WORLD EARLY TOXICITY TESTING MARKET, BY END USER

8.5.4   REST OF WORLD EARLY TOXICITY TESTING MARKET, BY COUNTRY

8.5.4.1.          LATIN AMERICA

8.5.4.1.1.    LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.5.4.1.1.1.   LATIN AMERICA IN VITRO MARKET, BY TECHNIQUE

8.5.4.1.2.    LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.5.4.1.3.    LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY END USER

8.5.4.2.          MIDDLE EAST

8.5.4.2.1.    MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.5.4.2.1.1.   MIDDLE EAST IN VITRO MARKET, BY TECHNIQUE

8.5.4.2.2.    MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.5.4.2.3.    MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY END USER

8.5.4.3.          AFRICA

8.5.4.3.1.    AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

8.5.4.3.1.1.   AFRICA IN VITRO MARKET, BY TECHNIQUE

8.5.4.3.2.    AFRICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS

8.5.4.3.3.    AFRICA EARLY TOXICITY TESTING MARKET, BY END USER

9. COMPANY PROFILES

9.1.     INOTIV INC.

9.1.1   COMPANY OVERVIEW

9.1.2   COMPANY SNAPSHOT

9.1.3   OPERATING BUSINESS SEGMENTS

9.1.4   PRODUCT PORTFOLIO

9.1.5   BUSINESS PERFORMANCE

9.1.6   SALES BY BUSINESS SEGMENT

9.1.7   SALES BY GEOGRAPHIC SEGMENT

9.1.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.1.9   PRIMARY MARKET COMPETITORS

9.2.     BIO-RAD LABORATORIES INC

9.2.1   COMPANY OVERVIEW

9.2.2   COMPANY SNAPSHOT

9.2.3   OPERATING BUSINESS SEGMENTS

9.2.4   PRODUCT PORTFOLIO

9.2.5   BUSINESS PERFORMANCE

9.2.6   SALES BY BUSINESS SEGMENT

9.2.7   SALES BY GEOGRAPHIC SEGMENT

9.2.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.2.9   PRIMARY MARKET COMPETITORS

9.3.     EVOTEC A.G.

9.3.1   COMPANY OVERVIEW

9.3.2   COMPANY SNAPSHOT

9.3.3   OPERATING BUSINESS SEGMENTS

9.3.4   PRODUCT PORTFOLIO

9.3.5   BUSINESS PERFORMANCE

9.3.6   SALES BY BUSINESS SEGMENT

9.3.7   SALES BY GEOGRAPHIC SEGMENT

9.3.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.3.9   PRIMARY MARKET COMPETITORS

9.4.     AGILENT TECHNOLOGIES INC

9.4.1   COMPANY OVERVIEW

9.4.2   COMPANY SNAPSHOT

9.4.3   OPERATING BUSINESS SEGMENT

9.4.4   PRODUCT PORTFOLIO

9.4.5   BUSINESS PERFORMANCE

9.4.6   SALES BY BUSINESS SEGMENT

9.4.7   SALES BY GEOGRAPHIC SEGMENT

9.4.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.4.9   PRIMARY MARKET COMPETITORS

9.5.     WUXI APPTEC

9.5.1   COMPANY OVERVIEW

9.5.2   COMPANY SNAPSHOT

9.5.3   OPERATING BUSINESS SEGMENTS

9.5.4   PRODUCT PORTFOLIO

9.5.5   BUSINESS PERFORMANCE

9.5.6   SALES BY BUSINESS SEGMENT

9.5.7   SALES BY GEOGRAPHIC SEGMENT

9.5.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.5.9   PRIMARY MARKET COMPETITORS

9.6.     BRUKER

9.7.1   COMPANY OVERVIEW

9.7.2   COMPANY SNAPSHOT

9.7.3   OPERATING BUSINESS SEGMENT

9.7.4   PRODUCT PORTFOLIO

9.7.5   BUSINESS PERFORMANCE

9.7.6   SALES BY BUSINESS SEGMENT

9.7.7   SALES BY GEOGRAPHIC SEGMENT

9.7.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.7.9   PRIMARY MARKET COMPETITORS

9.7.     PERKINELMER INC.

9.8.1   COMPANY OVERVIEW

9.8.2   COMPANY SNAPSHOT

9.8.3   OPERATING BUSINESS SEGMENT

9.8.4   PRODUCT PORTFOLIO

9.8.5   BUSINESS PERFORMANCE

9.8.6   SALES BY BUSINESS SEGMENT

9.8.7   SALES BY GEOGRAPHIC SEGMENT

9.8.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.8.9   PRIMARY MARKET COMPETITORS

9.8.     ENZO BIOCHEM INC.

9.9.1   COMPANY OVERVIEW

9.9.2   COMPANY SNAPSHOT

9.9.3   OPERATING BUSINESS SEGMENT

9.9.4   PRODUCT PORTFOLIO

9.9.5   BUSINESS PERFORMANCE

9.9.6   SALES BY BUSINESS SEGMENT

9.9.7   SALES BY GEOGRAPHIC SEGMENT

9.9.8   KEY STRATEGIC MOVES & DEVELOPMENTS

9.9.9   PRIMARY MARKET COMPETITORS

9.9.   DANAHER CORPORATION

9.10.1 COMPANY OVERVIEW

9.10.2 COMPANY SNAPSHOT

9.10.3 OPERATING BUSINESS SEGMENTS

9.10.4 PRODUCT PORTFOLIO

9.10.5 BUSINESS PERFORMANCE

9.10.6 SALES BY BUSINESS SEGMENT

9.10.7 KEY STRATEGIC MOVES & DEVELOPMENTS

9.10.8 PRIMARY MARKET COMPETITORS

9.10.   EUROFINS SCIENTIFIC SE

9.11.1 COMPANY OVERVIEW

9.11.2 COMPANY SNAPSHOT

9.11.3 PRODUCT PORTFOLIO

9.11.4 BUSINESS PERFORMANCE

9.11.5 SALES BY GEOGRAPHIC SEGMENT

9.11.6 KEY STRATEGIC MOVES & DEVELOPMENTS

9.11.7 PRIMARY MARKET COMPETITORS

9.11.   CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

9.12.1 COMPANY OVERVIEW

9.12.2 COMPANY SNAPSHOT

9.12.3 OPERATING BUSINESS SEGMENTS

9.12.4 PRODUCT PORTFOLIO

9.12.5 BUSINESS PERFORMANCE

9.12.6 SALES BY BUSINESS SEGMENT

9.12.7 SALES BY GEOGRAPHIC SEGMENT

9.12.8 KEY STRATEGIC MOVES & DEVELOPMENTS

9.12.9 PRIMARY MARKET COMPETITORS

9.12.   LABCORP DRUG DEVELOPMENT.

9.13.1 COMPANY OVERVIEW

9.13.2 COMPANY SNAPSHOT

9.13.3 OPERATING BUSINESS SEGMENTS

9.13.4 PRODUCT PORTFOLIO

9.13.5 BUSINESS PERFORMANCE

9.13.6 SALES BY BUSINESS SEGMENT

9.13.7 SALES BY GEOGRAPHIC SEGMENT

9.13.8 KEY STRATEGIC MOVES & DEVELOPMENTS

9.13.9 PRIMARY MARKET COMPETITORS

9.13.   PROMEGA CORPORATION

9.14.1 COMPANY OVERVIEW

9.14.2 COMPANY SNAPSHOT

9.14.3 PRODUCT PORTFOLIO

9.14.4 KEY STRATEGIC MOVES & DEVELOPMENTS

9.14.5 PROMEGA CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

9.14.6 PRIMARY MARKET COMPETITORS

9.14.   INSPHERO AG

9.15.1 COMPANY OVERVIEW

9.15.2 COMPANY SNAPSHOT

9.15.3 PRODUCT PORTFOLIO

9.15.4 KEY STRATEGIC MOVES & DEVELOPMENTS

9.15.5 INSPHERO AG: KEY STRATEGIC MOVES & DEVELOPMENTS

9.15.6 PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 2. IN VIVO MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 3. GLOBAL IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 4. CELL CULTURE MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 5. PCR MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 6. ELISA MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 7. WESTERN BLOTTING MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 8. PROTEIN BINDING ASSAYS MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 9. IN VITRO MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 10. IN SILICO MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 11. GLOBAL EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 12. GENOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 13. DERMAL TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 14. SKIN TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 15. OCULAR TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 16. PHOTOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 17. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 18. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 19. PHARMACEUTICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 20. COSMETIC INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 21. CHEMICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 22. FOOD INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 23. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 24. GLOBAL EARLY TOXICITY TESTING MARKET, BY REGION, 2022-2030, MILLION USD

TABLE 25. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 26. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 27. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 28. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 29. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 30. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 31. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 32. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 33. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 34. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 35. CANADA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 36. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 37. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 38. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 39. MEXICO IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 40. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 41. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 42. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 43. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 44. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 45. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 46. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 47. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 48. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 49. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 50. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 51. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 52. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 53. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 54. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 55. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 56. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 57. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 58. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 59. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 60. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 61. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 62. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 63. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 64. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 65. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 66. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 67. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 68. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 69. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 70. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 71. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 72. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 73. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 74. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 75. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 76. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 77. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 78. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 79. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 80. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 81. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 82. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 83. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 84. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 85. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 86. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 87. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 88. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 89. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 90. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 91. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 92. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 93. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 94. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 95. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 96. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 97. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 98. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 99. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 100. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 101. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 102. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 103. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 104. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 105. CHINA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 106. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 107. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 108. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 109. INDIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 110. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 111. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 112. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 113. INDONESIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 114. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 115. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 116. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 117. JAPAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 118. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 119. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 120. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 121. SINGAPORE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 122. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 123. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 124. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 125. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 126. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 127. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 128. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 129. TAIWAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 130. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 131. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 132. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 133. THAILAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 134. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 135. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 136. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 137. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 138. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 139. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 140. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 141. REST OF WORLD IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 142. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 143. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 144. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 145. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 146. LATIN AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 147. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 148. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 149. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 150. MIDDLE EAST IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 151. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 152. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 153. AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 154. AFRICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 155. AFRICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 156. AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 157. INOTIV INC.: COMPANY SNAPSHOT

TABLE 158. INOTIV INC: OPERATING SEGMENTS

TABLE 159. INOTIV INC.: PR0DUCT PORTFOLIO

TABLE 160. INOTIV INC.: BUSINESS SEGMENT

TABLE 161. INOTIV INC.: GEOGRAPHIC SEGMENT

TABLE 162. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 163. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 164. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 165. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 166. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT

TABLE 167. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT

TABLE 168. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 169. EVOTEC A.G.: COMPANY SNAPSHOT

TABLE 170. EVOTEC A.G.: OPERATING SEGMENTS

TABLE 171. EVOTEC A.G.: PRODUCT PORTFOLIO

TABLE 172. EVOTEC A.G.: BUSINESS SEGMENT

TABLE 173. EVOTEC A.G.: GEOGRAPHIC SEGMENT

TABLE 174. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 175. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 176. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 177. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 178. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT

TABLE 179. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT

TABLE 180. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 181. WUXI APPTEC.: COMPANY SNAPSHOT

TABLE 182. WUXI APPTEC: OPERATING SEGMENTS

TABLE 183. WUXI APPTEC.: PR0DUCT PORTFOLIO

TABLE 184. WUXI APPTEC.: BUSINESS SEGMENT

TABLE 185. WUXI APPTEC.: GEOGRAPHIC SEGMENT

TABLE 186. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 187. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 188. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 189. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 190. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 191. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 192. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 193. BRUKER: COMPANY SNAPSHOT

TABLE 194. BRUKER: OPERATING SEGMENTS

TABLE 195. BRUKER: PRODUCT PORTFOLIO

TABLE 196. BRUKER: BUSINESS SEGMENT

TABLE 197. BRUKER: GEOGRAPHIC SEGMENT

TABLE 198. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 199. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 200. PERKINELMER INC.: OPERATING SEGMENTS

TABLE 201. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 202. PERKINELMER INC.: BUSINESS SEGMENT

TABLE 203. PERKINELMER INC.: GEOGRAPHIC SEGMENT

TABLE 204. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 205. ENZO BIOCHEM INC.: COMPANY SNAPSHOT

TABLE 206. ENZO BIOCHEM INC.: OPERATING SEGMENTS

TABLE 207. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO

TABLE 208. ENZO BIOCHEM INC.: BUSINESS SEGMENT

TABLE 209. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT

TABLE 210. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 211. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 212. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 213. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 214. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 215. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 216. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT

TABLE 217. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO

TABLE 218. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT

TABLE 219. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 220. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT

TABLE 221. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS

TABLE 222. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO

TABLE 223. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT

TABLE 224. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT

TABLE 225. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 226. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT

TABLE 227. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS

TABLE 228. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO

TABLE 229. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT

TABLE 230. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT

TABLE 231. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 232. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 233. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 234. INSPHERO AG: COMPANY SNAPSHOT

TABLE 235. INSPHERO AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. MARKET SHARE ANALYSIS OF TOP EARLY TOXICITY TESTING PROVIDERS, 2022

FIGURE 2. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 3. IN VIVO MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 4. GLOBAL IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 5. CELL CULTURE MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 6. PCR MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 7. ELISA MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 8. WESTERN BLOTTING MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 9. PROTEIN BINDING ASSAYS MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 10. IN VITRO MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 11. IN SILICO MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 12. GLOBAL EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 13. GENOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 14. DERMAL TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 15. SKIN TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 16. OCULAR TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 17. PHOTOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 18. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 19. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 20. PHARMACEUTICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 21. COSMETIC INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 22. CHEMICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 23. FOOD INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 24. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 25. GLOBAL EARLY TOXICITY TESTING MARKET, BY REGION, 2022-2030, MILLION USD

FIGURE 26. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 27. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 28. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 29. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 30. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 31. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 32. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 33. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 34. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 35. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 36. CANADA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 37. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 38. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 39. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 40. MEXICO IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 41. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 42. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 43. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 44. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 45. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 46. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 47. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 48. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 49. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 50. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 51. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 52. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 53. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 54. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 55. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 56. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 57. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 58. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 59. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 60. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 61. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 62. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 63. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 64. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 65. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 66. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 67. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 68. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 69. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 70. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 71. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 72. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 73. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 74. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 75. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 76. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 77. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 78. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 79. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 80. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 81. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 82. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 83. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 84. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 85. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 86. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 87. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 88. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 89. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 90. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 91. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 92. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 93. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 94. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 95. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 96. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 97. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 98. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 99. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 100. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 101. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 102. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 103. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 104. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 105. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 106. CHINA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 107. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 108. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 109. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 110. INDIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 111. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 112. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 113. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 114. INDONESIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 115. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 116. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 117. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 118. JAPAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 119. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 120. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 121. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 122. SINGAPORE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 123. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 124. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 125. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 126. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 127. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 128. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 129. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 130. TAIWAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 131. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 132. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 133. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 134. THAILAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 135. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 136. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 137. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 138. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 139. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 140. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 141. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 142. REST OF WORLD IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 143. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 144. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 145. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 146. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 147. LATIN AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 148. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 149. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 150. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 151. MIDDLE EAST IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 152. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 153. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 154. AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 155. AFRICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 156. AFRICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 157. AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 158. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 159. INOTIV INC: PRIMARY MARKET COMPETITORS

FIGURE 160. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 161. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS

FIGURE 162. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)

FIGURE 163. EVOTEC A.G.: PRIMARY MARKET COMPETITORS

FIGURE 164. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)

FIGURE 165. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS

FIGURE 166. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 167. WUXI APPTEC: PRIMARY MARKET COMPETITORS

FIGURE 168. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 169. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 170. BRUKER: NET SALES, 2019–2021 ($MILLION)

FIGURE 171. BRUKER: PRIMARY MARKET COMPETITORS

FIGURE 172. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 173. PERKINELMER INC.: PRIMARY MARKET COMPETITORS

FIGURE 174. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 175. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS

FIGURE 176. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 177. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 178. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 179. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS

FIGURE 180. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 181. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS

FIGURE 182. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 183. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS

FIGURE 184. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 185. INSPHERO AG: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Inotiv Inc.

  • Bio-Rad Laboratories Inc

  • Evotec A.G. 

  • Agilent Technologies Inc

  • Wuxi Apptec

  • Bruker

  • Perkinelmer Inc.

  • Enzo Biochem Inc.

  • Danaher Corporation

  • Eurofins Scientific SE

  • Charles River Laboratories International, Inc.

  • Labcorp Drug Development.

  • Promega Corporation

  • Insphero AG

  • Thermo Fisher Scientific Inc.


Frequently Asked Questions
What are the benefits of in vitro toxicity testing?

? In vitro toxicity testing allows for the rapid screening of a large number of compounds, is less expensive than animal testing, and can provide insights into the mechanism of toxicity.

What are the limitations of in vitro toxicity testing?

In vitro, toxicity testing cannot completely replace in vivo animal testing as it cannot fully simulate the complex interactions that occur within living organisms.

What is computational toxicology?

Computational toxicology is the use of computational models and simulations to predict the toxicity of chemical compounds.

What are the benefits of computational toxicology?

Computational toxicology can help reduce the need for animal testing, is less expensive and time-consuming than traditional toxicity testing methods, and can provide insights into the mechanism of toxicity.

What are the limitations of computational toxicology?

Computational toxicology models are only as good as the data they are based on. There is a risk of false positives or negatives if the models are not properly validated.